SCHEMBL7530347

SCHEMBL7530347

N=C(N)NCCC[C@H](N)C(=O)NCCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
KMT2A Q03164 1/20 0.49
CNR1 P21554 1/20 0.48
MMP2 P08253 1/20 0.47
MMP8 P22894 2/20 0.47
HDAC8 Q9BY41 1/20 0.46
POLB P06746 1/20 0.46
PLAAT5 Q96KN8 3/20 0.46
PLAAT4 Q9UL19 3/20 0.46
PLAAT3 P53816 2/20 0.46
PLAAT2 Q9NWW9 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6380920 0.99 HDAC8 (0.48) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL7416564 0.88 MMP2 (0.48) MMP2MMP8
SCHEMBL7530381 0.88 MMP2 (0.48) MMP2MMP8
SCHEMBL7530376 0.88 MMP2 (0.48) MMP2MMP8
Homophenylalanine SCHEMBL20957448 0.85 GRIK1 (0.48) CYP2D6CYP2C9CYP2C19KMT2ACNR1
SCHEMBL27118430 0.84 MMP2 (0.50) MMP2
SCHEMBL22674667 0.84 NPY4R (0.51) KMT2AMMP8
SCHEMBL14444028 0.83 POLB (0.55) CYP2D6CYP2C9CYP2C19KMT2AMMP2
SCHEMBL30889119 0.82 MMP2 (0.67) CYP2D6CYP2C9CYP2C19KMT2AMMP2
SCHEMBL20257410 0.82 ALPI (0.50) HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363433-B1 PEPTIDE SYNTHESIS METHOD INVOLVING STERICALLY HINDERED MIXED ANHYDRIDE INTERMEDIATE AMICOAT AS (NO) 2025-10-08 EP disclosed
US-20240174713-A1 PEPTIDE SYNTHESIS METHOD INVOLVING STERICALLY HINDERED MIXED ANHYDRIDE INTERMEDIATE PHARMA HOLDINGS AS (NO) 2024-05-30 US disclosed
US-20230338609-A1 MEDICAL DEVICES AND MATERIALS COMPRISING BIODEGRADABLE POLYESTERS AMICOAT AS (NO) 2023-10-26 US disclosed
WO-2023275410-A1 PEPTIDE SYNTHESIS METHOD INVOLVING STERICALLY HINDERED MIXED ANHYDRIDE INTERMEDIATE AMICOAT AS (NO) 2023-01-05 WO disclosed
WO-2002024192-A1 DIPEPTIDE LIGANDS OF THE NPFF RECEPTOR FOR TREATING PAIN AND HYPERALGESIA INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174713-A1 PEPTIDE SYNTHESIS METHOD INVOLVING STERICALLY HINDERED MIXED ANHYDRIDE INTERMEDIATE VIP, GRPR, SSTR4 CYP2D6 3855/4885CYP2C9 4023/4885CYP2C19 3425/4885
US-20230338609-A1 MEDICAL DEVICES AND MATERIALS COMPRISING BIODEGRADABLE POLYESTERS AGXT, ECPAS, MLX CYP2D6 1297/4885CYP2C9 166/4885CYP2C19 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.